Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
BORTDEXALENA+DARA(SC); LENA+DARA(MNT-SC)
- Cancer Type
- Hematologic, Multiple Myeloma
- Intent
-
Palliative
- Regimen Category
-
Evidence-informed
- Funding Program
-
New Drug Funding Program Daratumumab (subcut) – Daratumumab in combination with Bortezomib, Lenalidomide and Dexamethasone - Newly Diagnosed Transplant Eligible Multiple Myeloma ODB Limited Use lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, who have stable disease or better, with no evidence of disease progression, according to specific criteria ODB - General Benefit dexamethasone
- Drugs Used
- daratumumab (subcut) , bortezomib , lenalidomide , dexamethasone
Regimen Monograph
Apr 2026
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
